A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Basit Öğe Kaydı
dc.authoridCekdemir, Demet/0000-0002-1881-5166
dc.authoridASLANER AK, Müzeyyen/0000-0001-6621-3138
dc.authoridUlu, Bahar Uncu/0000-0002-6230-9519
dc.authoridPehlivan, Mustafa/0000-0002-6692-085X
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridDemircioğlu, Sinan/0000-0003-1277-5105
dc.authoridErsoy Dursun, Fadime/0000-0002-3577-188X
dc.authorwosidÖzcan, Muhit/AAG-2251-2021
dc.authorwosidÖzcan, Mehmet Ali/Q-1897-2019
dc.authorwosidCekdemir, Demet/G-7958-2018
dc.authorwosidASLANER AK, Müzeyyen/AAB-7711-2022
dc.authorwosidUlu, Bahar Uncu/AAA-3636-2020
dc.authorwosidÖzkan, Hasan Atilla/GWQ-9284-2022
dc.authorwosidPehlivan, Mustafa/N-3210-2015
dc.contributor.authorCekdemir, Demet
dc.contributor.authorGuvenc, Serkan
dc.contributor.authorOzdemirkiran, Fusun
dc.contributor.authorEser, Ali
dc.contributor.authorTopts, Tayfur
dc.contributor.authorOzkocaman, Vildan
dc.contributor.authorSahin, Handan Haydaroglu
dc.date.accessioned2024-06-12T11:16:19Z
dc.date.available2024-06-12T11:16:19Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6 %; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm(3)) and defined as complete (platelet count of >100,000/mm(3)), partial (30,000-100,000/mm(3) or doubling of platelet count after treatment), or unresponsive (<30,000/mm(3)). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9 +/- 20.6 (range: 3-95) years and the duration of follow-up was 18.0 +/- 6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.en_US
dc.identifier.doi10.4274/tjh.galenos.2019.2018.0307
dc.identifier.endpage237en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4en_US
dc.identifier.pmid31327186en_US
dc.identifier.scopus2-s2.0-85075099354en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage230en_US
dc.identifier.trdizinid353770en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2019.2018.0307
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/353770
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24280
dc.identifier.volume36en_US
dc.identifier.wosWOS:000497303100003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectThrombocytopeniaen_US
dc.subjectImmune Thrombocytopenicen_US
dc.subjectEltrombopagen_US
dc.subjectLong-Termen_US
dc.subjectPurpuraen_US
dc.subjectSafetyen_US
dc.subjectAdultsen_US
dc.subjectItpen_US
dc.titleA Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu